Active	Status	Sponsor type	Region	Phase	Filter
11 Active 1 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « November » « 2025 » M T W T F S S 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30   - « November » « 2025 » M T W T F S S 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30   Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Mahtani, Reshma
SERIES, NCT06263543: Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC	Recruiting	2	75	US	Sacituzumab govitecan, Trodelvy	Reshma L. Mahtani, D.O., Gilead Sciences	Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer	06/26	12/26
ATEMPT 2.0, NCT04893109: Adjuvant T-DM1 vs TH	Recruiting	2	500	US	trastuzumab-emtansine, T-DM1, Kadcyla, Trastuzumab SC, Herceptin Hylecta, Paclitaxel, Taxol, Onxal	Dana-Farber Cancer Institute, Genentech, Inc.	Breast Cancer, HER2-positive Breast Cancer	11/26	05/28
NCT06100874: A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)	Recruiting	2	40	US	Sacituzumab Govitecan, Trodelvy, Trastuzumab, Herceptin, Trastuzumab and Hyaluronidase-oysk, Herceptin Hylecta	Adrienne G. Waks, Gilead Sciences	Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic	11/26	11/27
PERSEVERE, NCT04849364: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer	Terminated	2	52	US	Capecitabine, Xeloda, Talazoparib, Talzenna, Pembrolizumab, Keytruda, Inavolisib, GDC-0077	Bryan Schneider, MD, Genentech, Inc., Pfizer, Foundation Medicine, Indiana University, Vera Bradley Foundation for Breast Cancer	Breast Cancer, Triple Negative Breast Cancer	10/24	12/24
Amelia-1, NCT05455619: Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	Recruiting	1/2	52	US	Evexomostat, SDX-7320	SynDevRx, Inc.	HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer	03/26	09/26
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles	Recruiting	N/A	30000	Europe, Canada, US, RoW	MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint	Agendia	Breast Cancer	04/37	12/37
Fernandez, Krystal
SERIES, NCT06263543: Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC	Recruiting	2	75	US	Sacituzumab govitecan, Trodelvy	Reshma L. Mahtani, D.O., Gilead Sciences	Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer	06/26	12/26
Rader, Ryan
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Mahtani, Reshma
SERIES, NCT06263543: Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC	Recruiting	2	75	US	Sacituzumab govitecan, Trodelvy	Reshma L. Mahtani, D.O., Gilead Sciences	Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer	06/26	12/26
ATEMPT 2.0, NCT04893109: Adjuvant T-DM1 vs TH	Recruiting	2	500	US	trastuzumab-emtansine, T-DM1, Kadcyla, Trastuzumab SC, Herceptin Hylecta, Paclitaxel, Taxol, Onxal	Dana-Farber Cancer Institute, Genentech, Inc.	Breast Cancer, HER2-positive Breast Cancer	11/26	05/28
NCT06100874: A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)	Recruiting	2	40	US	Sacituzumab Govitecan, Trodelvy, Trastuzumab, Herceptin, Trastuzumab and Hyaluronidase-oysk, Herceptin Hylecta	Adrienne G. Waks, Gilead Sciences	Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic	11/26	11/27
PERSEVERE, NCT04849364: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer	Terminated	2	52	US	Capecitabine, Xeloda, Talazoparib, Talzenna, Pembrolizumab, Keytruda, Inavolisib, GDC-0077	Bryan Schneider, MD, Genentech, Inc., Pfizer, Foundation Medicine, Indiana University, Vera Bradley Foundation for Breast Cancer	Breast Cancer, Triple Negative Breast Cancer	10/24	12/24
Amelia-1, NCT05455619: Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	Recruiting	1/2	52	US	Evexomostat, SDX-7320	SynDevRx, Inc.	HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer	03/26	09/26
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles	Recruiting	N/A	30000	Europe, Canada, US, RoW	MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint	Agendia	Breast Cancer	04/37	12/37
Fernandez, Krystal
SERIES, NCT06263543: Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC	Recruiting	2	75	US	Sacituzumab govitecan, Trodelvy	Reshma L. Mahtani, D.O., Gilead Sciences	Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer	06/26	12/26
Rader, Ryan
No trials found